Streetbeat News

Stock Prices

UP

Wheels Up shares are experiencing a rise in trading following the announcement that 97.2% of lead investor shares will remain under a lock-up restriction until September 20, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:48 am

BDTX

Black Diamond Therapeutics shares rose following positive initial Phase 2 data for BDTX-1535, showing promising clinical responses in treating a specific type of lung cancer.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:45 am

AZN

AstraZeneca's Phase 3 trial of datopotamab deruxtecan (Dato-DXd) for breast cancer did not achieve statistical significance in overall survival, though it showed improvement in progression-free survival and patient-reported outcomes. The safety profile was consistent with previous analyses. AstraZeneca's stock is down 1.86% in premarket trading.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 11:44 am

BHVN

Biohaven shares rose after the company announced that its study of Troriluzole for treating spinocerebellar ataxia met the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:43 am

ALRN

Aileron Therapeutics has completed enrollment for the Phase 1b trial of its IPF drug, LTI-03. The trial aims to assess the safety and tolerability of the drug, with topline data expected soon. Positive trends were previously observed in the low-dose cohort.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:37 am

RKLB

ROKT

UFO

Rocket Lab USA, Inc. successfully launched its 53rd Electron mission, deploying five satellites for Kinéis, boosting its stock price. The mission supports global IoT connectivity, with Rocket Lab's stock gaining 71% over the past year. Investors can access RKLB through ETFs like Procure Space ETF and SPDR S&P Kensho Final Frontiers ETF.

Portfolio Pulse from Lekha Gupta

September 23, 2024 | 11:33 am

BHVN

Biohaven Ltd. (NYSE:BHVN) announced positive 3-year results for troriluzole in treating Spinocerebellar Ataxia (SCA), showing significant slowing of disease progression. The study met its primary endpoint, and Biohaven plans to submit a New Drug Application to the FDA in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:32 am

YOSH

Yoshiharu Global has filed for an offering of up to 400,000 shares, as indicated in their 424B4 filing. This move could impact the company's stock price and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:19 am

HLNE

Hamilton Lane (NASDAQ:HLNE) has been added to the S&P MidCap 400, marking a significant growth milestone. The firm, with over $940 billion in assets under management, continues to expand its private markets investment solutions.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:18 am

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) has published research demonstrating that its Pressure-Enabled Drug Delivery (PEDD) method significantly improves the delivery of glass microspheres into liver tumors compared to conventional methods. The study, conducted on a porcine liver tumor model, shows enhanced penetration and potential for more effective cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:14 am